Switch to:
GlaxoSmithKline PLC  (NYSE:GSK) Cash Flow from Financing: $-8,106 Mil (TTM As of Jun. 2017)

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the three months ended in Jun. 2017, GlaxoSmithKline PLC received $17 Mil more from issuing new shares than it paid to buy back shares. It received $1,170 Mil from issuing more debt. It paid $0 Mil more to buy back preferred shares than it received from issuing preferred shares. It spent $1,439 Mil paying cash dividends to shareholders. It spent $983 Mil on other financial activities. In all, GlaxoSmithKline PLC spent $1,236 Mil on financial activities for the three months ended in Jun. 2017.


Historical Data

* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.

* Premium members only.

GlaxoSmithKline PLC Annual Data

Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16
Cash Flow from Financing Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5,413.57 -10,283.61 -8,427.23 -10,633.23 -7,980.02

GlaxoSmithKline PLC Quarterly Data

Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17
Cash Flow from Financing Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1,663.35 -2,582.13 -2,425.72 -1,862.96 -1,235.60

Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

GlaxoSmithKline PLC's Cash from Financing for the fiscal year that ended in Dec. 2016 is calculated as:

Cash Flow from Financing(A: {A1})
=Net Issuance of Stock+Net Issuance of Debt+Net Issuance of Preferred Stock+Cash Flow for Dividends+Other Financing
=18.7265917603+184.769038702+0+-6054.93133583+-2128.58926342
=-7,980

GlaxoSmithKline PLC's Cash from Financing for the quarter that ended in Jun. 2017 is

Cash Flow from Financing(Q: Jun. 2017 )
=Net Issuance of Stock+Net Issuance of Debt+Net Issuance of Preferred Stock+Cash Flow for Dividends+Other Financing
=16.6453265045+1170.29449424+{NetIssuanceofpreferred_last}}+-1439.18053777+-983.354673496
=-1,236

Cash Flow from Financing for the trailing twelve months (TTM) ended in Jun. 2017 was -2582.12877792 (Sep. 2016 ) + -2425.71785268 (Dec. 2016 ) + -1862.96296296 (Mar. 2017 ) + -1235.59539052 (Jun. 2017 ) = $-8,106 Mil.

* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.


Explanation

Cash from financing contains five items:

1. Net Issuance of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. If this number is positive, it means that the company has received more cash from issuing shares than it has paid to buy back shares. If this number is negative, it means that company has paid more cash to buy back shares than it has received for issuing shares.

GlaxoSmithKline PLC's net issuance of stock for the three months ended in Jun. 2017 was $17 Mil. GlaxoSmithKline PLC received $17 Mil more from issuing new shares than it paid to buy back shares.

2. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

GlaxoSmithKline PLC's net issuance of debt for the three months ended in Jun. 2017 was $1,170 Mil. GlaxoSmithKline PLC received $1,170 Mil from issuing more debt.

3. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

GlaxoSmithKline PLC's net issuance of preferred for the three months ended in Jun. 2017 was $0 Mil. GlaxoSmithKline PLC paid $0 Mil more to buy back preferred shares than it received from issuing preferred shares.

4. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

GlaxoSmithKline PLC's cash flow for dividends for the three months ended in Jun. 2017 was $-1,439 Mil. GlaxoSmithKline PLC spent $1,439 Mil paying cash dividends to shareholders.

5. Other Financing:
Money spent or earned by company from other financial activities.

GlaxoSmithKline PLC's other financing for the three months ended in Jun. 2017 was $-983 Mil. GlaxoSmithKline PLC spent $983 Mil on other financial activities.


Related Terms


Headlines

No Headline

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}
FEEDBACK